Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia | Zendy

Barbara Jones | Zendy; Jian Ying | Zendy; Vanessa Stevens | Zendy; Candace Haroldsen | Zendy; Tao He | Zendy; McKenevers | Zendy; Matthew A. Christensen | Zendy; Richard E. Nelson | Zendy; Gregory J. Stoddard | Zendy; Brian C. Sauer | Zendy; Peter M. Yarbrough | Zendy; Makoto Jones | Zendy; Matthew Bidwell Goetz | Zendy; Tom Greene | Zendy; Matthew H. Samore | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia

Author(s) -

Barbara Jones,

Jian Ying,

Vanessa Stevens,

Candace Haroldsen,

Tao He,

McKenevers,

Matthew A. Christensen,

Richard E. Nelson,

Gregory J. Stoddard,

Brian C. Sauer,

Peter M. Yarbrough,

Makoto Jones,

Matthew Bidwell Goetz,

Tom Greene,

Matthew H. Samore

Publication year - 2020

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2019.7495

Subject(s) - medicine , pneumonia , antibiotic therapy , antibiotics , empirical treatment , intensive care medicine , emergency medicine , microbiology and biotechnology , biology

Use of empirical broad-spectrum antibiotics for pneumonia has increased owing to concern for resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA). The association of empirical anti-MRSA therapy with outcomes among patients with pneumonia is unknown, even for high-risk patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research